DalGenE

 

Clinical Area

 

Acute Coronary Syndrome

Study Title DalGenE
Purpose of Research A Phase III, double-blind, randomized placebo-controlled study to evaluate the effects of Dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent acute coronary syndrome (ACS).
Participant Description Patients who have recently been hospitalized for an Acute Coronary Syndrome (ACS) which is a myocardial infarction or ischemia. Patients who are selected as a possible participant in this study because they have a high risk of experiencing another cardiovascular event.
Principal Investigator Daniel Spoon, MD
Study Coordinator Kelli Hoffman, RN
Study Status Enrolling